Johnson & Johnson (JNJ +1.3%) unit Janssen Pharmaceutical Companies is collaborating with Boston’s Beth Israel Deaconess Medical Center on the development of a preventative vaccine against COVID-19.
Preclinical testing is underway. The parties
expect to identify a candidate by month-end and commence a Phase 1 study
by year-end.
The vaccine will be based on Janssen’s AdVac and PER.C6 technologies.
https://seekingalpha.com/news/3551589-j-and-j-launches-covidminus-19-vaccine-program
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.